An expected, FDA approval of the type 2 diabetes drug Adlyxin (lixisenatide) finally arrived for Sanofi SA, following initial withdrawal of a new drug application in late 2013 as the French drugmaker sought to establish cardiovascular safety of the GLP-1 receptor agonist.